The pathogenesis of diverticular disease is still poorly understood and considered to be multifactorial. Whereas classical pathogenetic concepts have focused on risk factors including increasing age, low-fiber diet and connective tissue disorders, novel concepts take into account that patients with diverticular disease exhibit disturbed intestinal motility patterns (that may result in functional obstruction and painful sensations) therefore postulating an underlying enteric neuro-/myopathy. Recent studies including quantitative evaluations of the enteric nervous system (ENS) in diverticular disease yielded hypoganglionic conditions of both myenteric and submucosal plexus as well as a nerve tissue remodeling in chronic diverticular disease. The disturbed neuromuscular communication was proven by demonstrating alterations in several enteric neurotransmitter systems, exemplified for the cholinergic, serotonergic, nitrergic system as well as for vasointestinal peptide, galanin and tachykinins. Novel lines of evidence have added the involvement of neurotrophic factors such as glial cell line-derived neurotrophic factor which is supposed to regulate ENS development and maintenance and which is downregulated in patients with diverticular disease. Consistent with the hypothesis of an enteric myopathy, deficits in smooth muscle integrity and composition such as hypertrophy, fibrotic transformation and gene expression deficits could be delineated. Taken together, the structural and functional findings on alterations of the ENS and the enteric musculature in diverticular disease provide evidence to strengthen the hypothesis that an enteric neuro-/myopathy may contribute to the development of colonic diverticula and the generation of symptoms in the course of the disease.

Keywords:
Pathogenesis, Enteric nervous system, Enteric neuropathy, Enteric myopathy
1.
Sandler RS, et al: The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500–1511.
2.
Parks TG: Post-mortem studies on the colon with special reference to diverticular disease. Proc R Soc Med 1968;61:932–934.
3.
Hughes LE: Postmortem survey of diverticular disease of the colon. II. The muscular abnormality of the sigmoid colon. Gut 1969;10:344–351.
4.
Painter NS, Burkitt DP: Diverticular disease of the colon, a 20th century problem. Clin Gastroenterol 1975;4:3–21.
5.
Miura S, et al: Recent trends in diverticulosis of the right colon in Japan: retrospective review in a regional hospital. Dis Colon Rectum 2000;43:1383–1389.
6.
Painter NS: The cause of diverticular disease of the colon, its symptoms and its complications. Review and hypothesis. J R Coll Surg Edinb 1985;30:118–122.
7.
Gear JS, et al: Symptomless diverticular disease and intake of dietary fibre. Lancet 1979;i:511–514.
8.
Wess L, et al: An association between maternal diet and colonic diverticulosis in an animal model. Gut 1996;39:423–427.
9.
Burkitt DP, Walker AR, Painter NS: Effect of dietary fibre on stools and the transit-times, and its role in the causation of disease. Lancet 1972;ii:1408–1412.
10.
Wess L, et al: Cross linking of collagen is increased in colonic diverticulosis. Gut 1995;37:91–94.
11.
Thomson HJ, et al: The submucosa of the human colon. J Ultrastruct Mol Struct Res 1986;96:22–30.
12.
Whiteway J, Morson BC: Elastosis in diverticular disease of the sigmoid colon. Gut 1985;26:258–266.
13.
Stumpf M, et al: Increased distribution of collagen type III and reduced expression of matrix metalloproteinase 1 in patients with diverticular disease. Int J Colorectal Dis 2001;16:271–275.
14.
Mimura T, et al: Up-regulation of collagen and tissue inhibitors of matrix metalloproteinase in colonic diverticular disease. Dis Colon Rectum 2004;47:371–378; discussion 378–379.
15.
Arfwidsson S, et al: Pathogenesis of multiple diverticula of the sigmoid colon in diverticular disease. Acta Chir Scand 1964;63:(suppl 342):1–68.
16.
Painter NS, et al: Effect of morphine, prostigmine, pethidine, and probanthine on the human colon in diverticulosis studied by intraluminal pressure recording and cineradiography. Gut 1965;6:57–63.
17.
Weinreich J, Andersen D: Intraluminal pressure in the sigmoid colon. II. Patients with sigmoid diverticula and related conditions. Scand J Gastroenterol 1976;11:581–586.
18.
Trotman IF, Misiewicz JJ: Sigmoid motility in diverticular disease and the irritable bowel syndrome. Gut 1988;29:218–222.
19.
Cortesini C, Pantalone D: Usefulness of colonic motility study in identifying patients at risk for complicated diverticular disease. Dis Colon Rectum 1991;34:339–342.
20.
Bassotti G, et al: Twenty-four hour recordings of colonic motility in patients with diverticular disease: evidence for abnormal motility and propulsive activity. Dis Colon Rectum 2001;44:1814–1820.
21.
Knowles CH, et al: The London Classification of gastrointestinal neuromuscular pathology: report on behalf of the Gastro 2009 International Working Group. Gut 2010;59:882–887.
22.
Macbeth WA, Hawthorne JH: Intramural ganglia in diverticular disease of the colon. J Clin Pathol 1965;18:40–42.
23.
Vuong NP, et al: Myenteric plexuses and colonic diverticulosis: results of a histological study. Gastroenterol Clin Biol 1985;9:434–436.
24.
Iwase H, et al: Morphology of myenteric plexuses in the human large intestine: comparison between large intestines with and without colonic diverticula. J Clin Gastroenterol 2005;39:674–678.
25.
Deduchovas O, et al: Morphologic pattern of myenteric neural plexus in colonic diverticular disease. A whole-mount study employing histochemical staining for acetylcholinesterase. Ann Anat 2008;190:525–530.
26.
Bassotti G, et al: Interstitial cells of Cajal, enteric nerves, and glial cells in colonic diverticular disease. J Clin Pathol 2005;58:973–977.
27.
Golder M, et al: Smooth muscle cholinergic denervation hypersensitivity in diverticular disease. Lancet 2003;361:1945–1951.
28.
Stoss F, Meier-Ruge W: Diagnosis of neuronal colonic dysplasia in primary chronic constipation and sigmoid diverticulosis endoscopic biopsy and enzyme-histochemical examination. Surg Endosc 1991;5:146–149.
29.
Meier-Ruge W, et al: The neuropathological diagnosis of neuronal intestinal dysplasia (NID B). Eur J Pediatr Surg 1994;4:267–273.
30.
Wedel T, et al: Diverticular disease is associated with an enteric neuropathy as revealed by morphometric analysis. Neurogastroenterol Motil 2010;22:407–414, e93–e94.
31.
Morson BC: The muscle abnormality in diverticular disease of the colon. Proc R Soc Med 1963;56:798–800.
32.
Raguse T, Kuhnel W: Pathogenesis of colon diverticular disease (author’s transl). Leber Magen Darm 1981;11:147–158.
33.
Milner P, et al: Vasoactive intestinal polypeptide levels in sigmoid colon in idiopathic constipation and diverticular disease. Gastroenterology 1990;99:666–675.
34.
Golder M, et al: Longitudinal muscle shows abnormal relaxation responses to nitric oxide and contains altered levels of NOS1 and elastin in uncomplicated diverticular disease. Colorectal Dis 2007;9:218–228.
35.
Simpson J, et al: Post inflammatory damage to the enteric nervous system in diverticular disease and its relationship to symptoms. Neurogastroenterol Motil 2009;21:847–e858.
36.
Gershon MD: Review article: serotonin receptors and transporters – roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004;20(suppl 7):3–14.
37.
Kuemmerle JF, et al: Coexpression of 5-HT2A and 5-HT4 receptors coupled to distinct signaling pathways in human intestinal muscle cells. Gastroenterology 1995;109:1791–1800.
38.
Lin LF, et al: Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. J Neurochem 1994;63:758–768.
39.
Bottner M, Krieglstein K, Unsicker K: The transforming growth factor-betas: structure, signaling, and roles in nervous system development and functions. J Neurochem 2000;75:2227–2240.
40.
Airaksinen MS, Saarma M: The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002;3:383–394.
41.
Moore MW, et al: Renal and neuronal abnormalities in mice lacking GDNF. Nature 1996;382:76–79.
42.
Durbec P, et al: GDNF signalling through the Ret receptor tyrosine kinase. Nature 1996;381:789–793.
43.
Cacalano G, et al: GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney. Neuron 1998;21:53–62.
44.
Attie T, et al: Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet 1995;4:1381–1386.
45.
Brian West A: The pathology of diverticulosis: classical concepts and mucosal changes in diverticula. J Clin Gastroenterol 2006;40(suppl 3):S126–S131.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.